Introduction
============

Estradiol is a key factor for tumorigenesis and prognosis of hormone receptor (HR)-positive breast cancer. Although estradiol is produced mainly by the ovary in premenopausal women, the adrenal gland and adipocytes are also sources of lesser amounts of estradiol ([@bib1], [@bib2], [@bib3]). Therefore, obesity, a medical condition with excess adipose tissue, has been explored as a risk factor and prognosis marker for a poor outcome in patients with HR-positive breast cancer. The effect of obesity on the prognosis of breast cancer is magnified in menopausal women and those with suppressed ovarian function. Importantly, the prognosis of menopausal patients with breast cancer is affected by obesity; this might arise from elevated aromatase in adipose tissue ([@bib4], [@bib5], [@bib6], [@bib7], [@bib8]).

Phosphorylated ribosomal protein S6 kinase-1 (pS6K1) is an effector of mammalian target of rapamycin activity in tumors and was recently identified as a biomarker for adipogenesis in the field of obesity ([@bib9]). Theoretically, high expression of S6K1 in a tumor may be related to adipogenesis on the tumor itself or in the tumor micro-environment and may stimulate the local estradiol concentration ([@bib10], [@bib11], [@bib12]). In our previous study, pS6K1 overexpression was associated with a worse prognosis in HR-positive breast cancer ([@bib13]). The study included patients that underwent surgery between January 1999 and January 2002. During that period, selective estrogen receptor modulator (SERM) treatment was the only adjuvant endocrine therapy regimen that was reimbursed by the national health insurance in South Korea for HR-positive breast cancer. Consequently, the majority of patients included in that analysis were treated by adjuvant SERM monotherapy, without any estradiol depletion regimen regardless of menopausal status ([@bib13]).

In several recent pre-clinical studies, estradiol suppresses adipogenesis and activates brown adipose tissue ([@bib14], [@bib15]). It might be a mechanism of action of estrogen replacement therapy, which has a beneficial effect on reducing cerebrovascular events in healthy postmenopausal women. However, concerning the breast cancer, the excess exposure to the high level of estradiol such as has long-term hormone replacement therapy, early menarche, late menopause or obesity has been suspected as risk factors of the hormone susceptible breast cancer ([@bib16]). Once the breast cancer developed, the breast adipose tissue bearing a tumor overexpresses aromatase, leading to local overproduction of estrogen that exerts paracrine and intracrine tumorigenic effects ([@bib17]). As a consequence of the process, the level of estradiol in tumor of breast cancer is significantly higher compared with circulating level in [@bib18], [@bib19].

Tamoxifen is a representative SERM. It functions as a competitive partial agonist for the estrogen receptor. The antitumor effect of tamoxifen is diminished when the estradiol level is high ([@bib20]). We assumed that the poor prognosis of patients with pS6K1-positive tumors who were treated by an adjuvant SERM was caused by the high local estradiol level resulting from local adipogenesis based on a recent report about pS6K1 and obesity ([@bib9]). In addition, we hypothesized that estradiol depletion therapy might be more effective in patients with pS6K1-positive than -negative tumors.

Estrogen depletion therapy was developed for treating HR-positive breast cancer in recent decades. Gonadotropin-releasing hormone (GnRH) agonists are specific estradiol depletion therapy for premenopausal women. According to the ESO-ESMO 3rd International Consensus Guidelines for treating breast cancer in young women, ovarian function suppression is recommended. However, they also recommend that this treatment be given only if it is tolerable ([@bib21]). Menopausal symptoms caused by a GnRH agonist could decrease the tolerability of this treatment. In addition, GnRH agonists can have adverse effects on bone health. For these reasons, a marker for the efficacy of GnRH agonists is required. In this study, we evaluated the effect of a GnRH agonist on disease-free survival based on the expression of pS6K1 in women with HR-positive, human epithelial growth factor 2 (HER2)-negative breast cancer.

Methods
=======

In this retrospective study, we included premenopausal women under 45 years of age with HR-positive, HER2-negative breast cancer. Patients with a history of other primary malignancies and *de novo* stage IV breast cancer were excluded. Patients who received adjuvant cyclophosphamide, methotrexate and fluorouracil (CMF) therapy were also excluded because of the higher rate of chemotherapy-induced amenorrhea ([@bib22], [@bib23]). Values for analyses were obtained from the patients' medical records. These included immunohistochemical analyses for pS6K1 expression, HR status and HER2 status, and other clinical factors (i.e., age at the time of diagnosis, tumor size, lymph node status, mammographic density and patient outcomes). This study was approved by the Institutional Review Board of Korea Cancer Center Hospital (IRB No. 2017-12-010). Informed consent was waived because this was retrospective study.

Immunohistochemical staining of the estrogen, progesterone and HER2 receptors, and pS6K1 was performed on core needle biopsy specimens obtained at the time of diagnosis or surgical specimens obtained at the time of curative surgery. Mouse monoclonal antibodies against human pS6K1 (Cell Signaling Technology; dilution 1:50), and estrogen, progesterone and HER2 receptors, were used as the primary antibodies ([@bib13]). Experienced pathologists interpreted the immunoreactivity of all results including pS6K1 expression. Results were reported officially and included in the medical records as a routine clinical practice. The expression of pS6k1 was categorized according to the immunohistochemical stain on cytosol or nucleus of tumor cells, and the stain was expressed on both nucleus and cytosol in majority of the cases. The pS6K1 expression status was scored from 0 to 3+; in this study, we classified 1+ to 3+ as positive and 0 as negative. Estrogen and progesterone receptor expression was calculated by the intensity score. A score of 0 was regarded as negative, while other scores were regarded as positive. HER2 expression was defined according to the American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline ([@bib24]). HER2 expression was scored from 0 to 3+. Scores of 0 and 1+ were classified as a negative reaction and 3+ was classified as a positive reaction. *In situ* hybridization was performed when immunohistochemistry showed a 2+ or greater result.

Mammographic breast density of patients was interpreted and reported officially by an experienced radiologist. The Breast Imaging Reporting and Data System for Breast Density Classification was used to define each group. Briefly, when glandular tissue was less than 25%, it was defined as grade 1. Glandular tissue of grade 2 ranged from 25 to 50% of the breast. Grade 3 represented heterogeneously dense breast tissue where the parenchyma ranged from 51 to 75%. Grade 4 contained more than 75% glandular and fibrous tissue ([@bib25]). Breast density reports were included in all medical records.

Pearson's chi-square test was used to assess the correlation between pS6K1 expression and other variables. Disease-free survival was defined as the time from diagnosis to the first event ending disease-free survival including locoregional recurrence, distant relapse, contralateral breast cancer, other primary cancer or death from any other cause. Survival analysis was constructed using the Kaplan--Meier method and differences were assessed using the log-rank test. Statistical significance was accepted for a *P* value of \<0.05.

Results
=======

Patient characteristics
-----------------------

A total of 296 patients were eligible for this analysis. The median follow-up period was 49.0 months (range: 1--114 months). Clinicopathological characteristics of the patients are listed in [Table 1](#tbl1){ref-type="table"}. Two hundred nineteen patients were categorized as pS6K1 positive (74.0%). The pS6K1-positive and -negative groups were well balanced in tumor size, nodal metastasis status, Ki67 status, surgical methods, BMI, serum estradiol levels and serum follicle-stimulating hormone levels at the time of diagnosis. There was no significant difference in BMI between the groups ([Table 1](#tbl1){ref-type="table"}). The relationship between breast density and pS6K1 expression was analyzed. Of the pS6K1-positive patients, 46.6% exhibited grade 4 mammographic breast density, while only 28.6% of the pS6K1-negative group had this density (*P* = 0.013, [Fig. 1](#fig1){ref-type="fig"}).Figure 1Breast density based on pS6K1 expression. Table 1Clinicopathologic characteristics of patients.pS6K1*P* valuePositive (*n* = 219)Negative (*n* = 77)Age (years, median)42.042.00.479Body mass index (kg/m^2^, median)\<25171 (78.1%)56 (72.7%)0.339≥2548 (21.9%)21 (27.3%)Serum estradiol (mIU/mL, median)89.367.50.495Follicle-stimulating hormone (pg/mL, median)5.845.760.961Ki67 (%, median)5.005.000.569Tumor size\<2 cm139 (63.5%)51 (66.2%)0.664≥2 cm80 (36.5%)26 (33.8%)Lymph node metastasisNegative133 (60.7%)44 (57.1%)0.581Positive86 (39.3%)33 (42.9%)Breast operationBreast-conserving surgery147 (67.1%)58 (75.3%)0.180Total mastectomy72 (32.9%)19 (24.7%)Adjuvant radiotherapyYes184 (84.0%)63 (81.8%)0.655No35 (16.0%)14 (18.2%)ChemotherapyNo74 (33.8%)37 (48.1%)0.024Regimen with taxane80 (36.5%)28 (36.4%)Regimen without taxane65 (29.7%)12 (15.6%)Endocrine therapyTamoxifen only108 (49.3%)23 (29.9%)0.003Tamoxifen + GnRH agonist111 (50.7%)54 (70.1%)[^1]

Disease-free survival according to the use of a GnRH agonist
------------------------------------------------------------

In pS6K1-positive patients treated with tamoxifen plus a GnRH agonist, disease-free survival was better than the tamoxifen-only group (hazard ratio 0.280, *P* = 0.018; [Fig. 2A](#fig2){ref-type="fig"}). The mean survival of the GnRH agonist group was 106.7 months and that of the tamoxifen only group was 91.1 months. In contrast, GnRH usage did not show significant clinical benefits in terms of disease-free survival in pS6K1-negative patients (hazard ratio 0.488, *P* = 0.464; [Fig. 2B](#fig2){ref-type="fig"}). Large tumor size and lymph node metastasis were related with poorer disease-free survival ([Table 2](#tbl2){ref-type="table"}).Figure 2Kaplan--Meier plots for disease-free survival comparing GnRH agonist usage in pS6K1-positive group (A), pS6K1-negative group (B). Table 2Univariate analysis for associated factors.FactorspS6K1Positive (*n* = 219)Negative (*n* = 77)CaseEventMean survival ± [s.d.]{.smallcaps} (month)*P* valueCaseEventMean survival ± [s.d.]{.smallcaps} (month)*P* valueTumor size\<2 cm1396104.8 ± 1.70.001513101.2 ± 3.70.580≥2 cm801590.7 ± 4.626196.2 ± 2.7Lymph node metastasisNegative1337103.5 ± 2.10.011441106.2 ± 1.70.088Positive861493.5 ± 4.233392.9 ± 5.7GnRH agonist usageYes1104106.7 ± 2.10.018542103.9 ± 2.70.464No1091791.1 ± 3.223297.8 ± 6.1ChemotherapyNo742106.3 ± 1.90.018371103 ± 4.50.910Regimen with taxane801493.2 ± 4.328194.8 ± 3.8Regimen without taxane65598.0 ± 3.012295.4 ± 8.3[^2]

Discussion
==========

In this study, pS6K1-positive patients treated with a GnRH agonist plus tamoxifen showed better disease-free survival than those given tamoxifen alone. In contrast, there was no significant difference regarding disease-free survival based on GnRH agonist treatment in pS6K1-negative patients. The percentage of pS6K1-positive patients with grade 4 breast density was higher than that in pS6K1-negative patients. Taken together, these findings indicate that pS6K1 may be considered a predictive marker for GnRH agonist efficacy in premenopausal women with HR-positive breast cancer and might correlate with the local estradiol level. To the best of our knowledge, this is the first study showing the clinical value of pS6K1 as a predictive biomarker for an endocrine therapy regimen in premenopausal patients.

Although we demonstrated the efficacy of pS6K1 as a biomarker for estrogen depletion treatment in premenopausal women, the exact mechanism is not well supported by pre-clinical studies ([@bib26], [@bib27]). In the breast cancer field, pS6K1 is considered to be a marker for proliferation ([@bib28]). In contrast, in the field of obesity, it is considered to be a key molecule in adipogenesis ([@bib29], [@bib30], [@bib31]). We hypothesized that pS6K1 might have an adipogenic effect on tumors or the tumor microenvironment and as a consequence might be involved with a local increase of estradiol levels ([@bib32]). Our current study demonstrated that breast tissue is relatively dense in patients with pS6K1-positive tumors. Because the relationship between breast density and the estradiol level is known, we hypothesized that dense breast tissue might be exposed to higher local estradiol levels that could arise because of pS6K1 positivity in HR-positive breast cancer.

The improved efficacy of adding a GnRH agonist in premenopausal women was elucidated by prospective randomized clinical trials such as the Suppression of Ovarian Function Trial (SOFT) and Addition of Ovarian Suppression to Tamoxifen in Young Women with Hormone-Sensitive Breast Cancer Who Remain Premenopausal or Regain Menstruation After Chemotherapy (ASTRRA) trial ([@bib33], [@bib34]). In SOFT, the 8-year disease-free survival rate was 78.9% with tamoxifen alone and 83.2% with tamoxifen plus ovarian suppression (*P* = 0.009). The 8-year overall survival rate was 91.5% with tamoxifen alone and 93.3% with tamoxifen plus ovarian suppression (*P* = 0.010) ([@bib34]). In the ASTRRA trial, the 5-year disease-free survival rate was 91.1% in the tamoxifen plus ovarian function suppression group and 87.5% in the tamoxifen only group (*P* = 0.033). The estimated overall survival rate after 5 years was 99.4% in the tamoxifen plus ovarian function suppression group and 97.8% in the tamoxifen only group (*P* = 0.029) ([@bib33]). However, GnRH agonist treatment can cause adverse events such as osteoporosis or menopausal symptoms ([@bib35], [@bib36], [@bib37]). Therefore, determining which patients may receive beneficial effects from GnRH agonist therapy should be evaluated carefully, and pS6k1 might be a clinically helpful marker.

A strength of our study was in the exclusion of patients treated with the CMF regimen. Earlier studies reported amenorrhea during adjuvant chemotherapy, and the CMF regimen can induce permanent amenorrhea frequently ([@bib22], [@bib23]). Because our study analyzed the effect of ovarian function suppression, chemotherapy-induced amenorrhea could have been a bias for the interpretation of our results. Moreover, we included only patients below 45 years of age at diagnosis, which was similar to the study population of the ASTRRA trial. In that trial, 57.5% of the patients treated by standard chemotherapy, except the CMF regimen, retained or regained ovarian function within 2 years of the completion of chemotherapy ([@bib33]). PS6K1 status is easy to obtain by immunohistochemistry. Another strong point of this analysis was the classification of pS6K1 expression on a 0--3+ scale. In our study, we set 1+--3+ as positive and 0 as negative and took measures to avoid bias from interpretation of the pS6K1 status.

A limitation of this study was its retrospective design that was conducted in a single institute. However, similar to many other biomarkers that are now used clinically in many kinds of tumors, results from this study provide helpful evidence to support conducting a prospective randomized controlled trial to evaluate precise endocrine therapy for premenopausal women with HR-positive, HER2-negative breast cancer.

In conclusion, pS6K1 is a potential biomarker for predicting the efficacy of GnRH agonist therapy in premenopausal patients with HR-positive, HER2-negative breast cancer. In such patients, estrogen depletion therapy, such as a GnRH agonist, might be offered more proactively.
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[^1]: GnRH, gonadotropin-releasing hormone.

[^2]: pS6K1, phosphorylated ribosomal protein S6 kinase-1; [s.d.]{.smallcaps}, standard deviation; GnRH, gonadotropin-releasing hormone.
